Vertex Pharmaceuticals in the news
Developing transformative medicines
Tamtam found 20 recent articles about Vertex Pharmaceuticals.
- Has Vertex Stock Become A Different Bet?
Vertex Pharmaceuticals is transitioning from a cystic fibrosis-dependent company to a diversified one by investing in new medicines across multiple disease areas, which is impacting its operating margins.
- Vertex Pharmaceuticals falls 2.94% in Thursday's session
Vertex Pharmaceuticals shares decreased by 2.94% to $520.66 on November 19, 2026, with a market value of $132.15 billion.
- 2 Growth Stocks to Buy in November Without Any Hesitation
Vertex Pharmaceuticals' core business remains robust with potential new drug approvals in kidney disease, while Regeneron is driven by strong Dupixent sales and a new Eylea formulation.
- At $547.86 apiece, a director sold 271 Vertex Pharmaceuticals (VRTX) shares.
A director at Vertex Pharmaceuticals sold 271 shares at $547.86 each.
- Genomics and Vertex Extend $220 million Drug Discovery Partnership Deal
Genomics and Vertex Pharmaceuticals extended their drug discovery partnership by four years for over $220 million, continuing to use human genetics to find new drug targets and develop precision medicines.
- After selling 1,000 shares of Vertex Pharmaceuticals (VRTX), Nancy Thornberry directly held 1,109.
An individual sold 1,000 shares of Vertex Pharmaceuticals (VRTX), reducing their direct holdings.
- Vertex Pharmaceuticals stock gains EUR 485.85, up 0.65%
Vertex Pharmaceuticals' stock rose as the company reported increased revenue and an upcoming FDA decision for a new drug.
- Vertex Pharmaceuticals (VRTX) Stock May Be Undervalued After Its 187% Run
Vertex Pharmaceuticals' stock has surged 186.8% over five years, with a Discounted Cash Flow analysis suggesting its intrinsic value is above the current share price.
- Should You Pick Vertex Stock Over Its Biotech Rivals?
Vertex Pharmaceuticals faces challenges with slow sales growth and a high stock valuation compared to competitors, despite its leading operating margin and reliance on cystic fibrosis treatments.
- VRTX Stock News Today: Latest Updates & Live Price | MEXC
Vertex Pharmaceuticals Inc. (VRTX) news, live price, and market updates are available.
- VRTX: Pivotal renal readouts and expanding non-CF revenue shape the 2027 outlook
Vertex Pharmaceuticals anticipates key renal trial results and continued non-CF revenue growth in 2027.
- Vertex Pharmaceuticals Eyes Nov. 30 Kidney Drug Decision as 2027 Pipeline Milestones Loom
Vertex Pharmaceuticals is nearing a Nov. 30 U.S. decision for its kidney drug povetacicept and anticipates multiple pipeline milestones through 2027, projecting significant growth in non-cystic fibrosis revenue.
- Vertex at Jefferies Global Healthcare Conference: kidney push builds
Vertex Pharmaceuticals is diversifying its portfolio beyond cystic fibrosis, with a strong focus on kidney disease treatments like povetacicept and inaxaplin, and anticipates significant non-cystic fibrosis revenue growth and pipeline advancements in 2027.
- Vertex Pharmaceuticals stock slips to EUR 487.60, down 1.28%
Vertex Pharmaceuticals' stock dropped 1.28% to EUR 487.60, as the company expands its drug pipeline beyond cystic fibrosis and anticipates an FDA decision on povetacicept.
- Will Vertex Pharmaceuticals (NASDAQ:VRTX) Turn Its Pipeline Into Momentum?
Vertex Pharmaceuticals is expanding its market reach with the successful launch of a non-opioid pain treatment and advancements in gene therapy, while maintaining strong performance in its cystic fibrosis franchise.
- Vertex on the verge of ‘iconic’ evolution as key kidney disease verdict looms
Vertex Pharmaceuticals is nearing a critical FDA decision for its kidney disease drug, povetacicept, which is expected to diversify its product portfolio beyond cystic fibrosis.
- Director Sangeeta N. Bhatia proposes selling 271 Vertex Pharmaceuticals (VRTX) shares.
A director at Vertex Pharmaceuticals plans to sell 271 common shares worth $148,470.06 around November 16, 2026.
- Vertex Pharmaceuticals stock at EUR 492.55, up 1.10%
Vertex Pharmaceuticals stock rose to EUR 492.55 on November 16, 2026, marking a 1.10% increase from its previous close.
- Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom
Vertex Pharmaceuticals anticipates a U.S. regulatory decision for its kidney drug, povetacicept, by November 30, while progressing multiple pipeline assets including treatments for kidney disease, chronic pain, and other conditions.
- Vertex Pharmaceuticals stock: Management's UBS conference appearance
Vertex Pharmaceuticals' management is participating in several investor conferences in November and December 2026, including UBS, Jefferies, and Evercore.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Vertex Pharmaceuticals?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies